Literature DB >> 7950508

Bone density and turnover in Addison's disease: effect of glucocorticoid treatment.

M A Valero1, M Leon, M P Ruiz Valdepeñas, L Larrodera, M B Lopez, K Papapietro, A Jara, F Hawkins.   

Abstract

Osteoporosis is a well-known side-effect of chronic treatment with glucocorticoids. We have studied vertebral bone mineral density (BMD) and biochemical markers of bone metabolism in 30 patients diagnosed of Addison's disease (AD) to determine the effect of long-term replacement treatment with hydrocortisone (30 mg/day) or prednisone (7.5 mg/day). Lumbar bone mineral density was measured with dual energy X-ray absorptiometry in L-1-4 in two occasions, separated by 12 months. BMD in premenopausal women and men with AD was similar to healthy controls and postmenopausal women had slightly lower results. Rate of change of bone density followed up over a period of 12 months was -0.82%. Bone loss was not influenced by duration or type of steroid treatment. Biochemical parameters, serum calcium, alkaline phosphatase, osteocalcin, procollagen type I, PTH and 25(OH)vitamin D were within normal limits. Our results show that in patients with AD, after replacement with low doses of glucocorticoids there is no significative trabecular bone loss neither modifications in bone formation markers.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7950508     DOI: 10.1016/s0169-6009(08)80158-4

Source DB:  PubMed          Journal:  Bone Miner        ISSN: 0169-6009


  9 in total

1.  Role of glucocorticoid-induced leucine zipper (GILZ) in bone acquisition.

Authors:  Guodong Pan; Jay Cao; Nianlan Yang; Kehong Ding; Cheng Fan; Wen-Cheng Xiong; Mark Hamrick; Carlos M Isales; Xing-Ming Shi
Journal:  J Biol Chem       Date:  2014-05-23       Impact factor: 5.157

2.  Vertebral fractures assessed with dual-energy X-ray absorptiometry in patients with Addison's disease on glucocorticoid and mineralocorticoid replacement therapy.

Authors:  Valentina Camozzi; Corrado Betterle; Anna Chiara Frigo; Veronica Zaccariotto; Martina Zaninotto; Erica De Caneva; Paola Lucato; Walter Gomiero; Silvia Garelli; Chiara Sabbadin; Monica Salvà; Miriam Dalla Costa; Marco Boscaro; Giovanni Luisetto
Journal:  Endocrine       Date:  2017-08-09       Impact factor: 3.633

3.  An Evidence-Based Model of Multidisciplinary Care for Patients and Families Affected by Classical Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency.

Authors:  Traci L Schaeffer; Jeanie B Tryggestad; Ashwini Mallappa; Adam E Hanna; Sowmya Krishnan; Steven D Chernausek; Laura J Chalmers; William G Reiner; Brad P Kropp; Amy B Wisniewski
Journal:  Int J Pediatr Endocrinol       Date:  2010-03-18

Review 4.  Therapy of adrenal insufficiency: an update.

Authors:  Alberto Falorni; Viviana Minarelli; Silvia Morelli
Journal:  Endocrine       Date:  2012-11-21       Impact factor: 3.633

5.  Usefulness of Time-Point Serum Cortisol and ACTH Measurements for the Adjustment of Glucocorticoid Replacement in Adrenal Insufficiency.

Authors:  Elise Rousseau; Michael Joubert; Géraldine Trzepla; Jean Jacques Parienti; Thomas Freret; Marie Christine Vanthygem; Rachel Desailloud; Hervé Lefebvre; Antoine Coquerel; Yves Reznik
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

6.  The contribution of serum cortisone and glucocorticoid metabolites to detrimental bone health in patients receiving hydrocortisone therapy.

Authors:  Rosemary Dineen; Lucy-Ann Behan; Grainne Kelleher; Mark J Hannon; Jennifer J Brady; Bairbre Rogers; Brian G Keevil; William Tormey; Diarmuid Smith; Christopher J Thompson; Malachi J McKenna; Wiebke Arlt; Paul M Stewart; Amar Agha; Mark Sherlock
Journal:  BMC Endocr Disord       Date:  2020-10-10       Impact factor: 2.763

7.  A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (Chronocort) vs. conventional hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia.

Authors:  Somya Verma; Carol Vanryzin; Ninet Sinaii; Mimi S Kim; Lynnette K Nieman; Shayna Ravindran; Karim A Calis; Wiebke Arlt; Richard J Ross; Deborah P Merke
Journal:  Clin Endocrinol (Oxf)       Date:  2009-05-25       Impact factor: 3.478

8.  Prednisolone is associated with a worse bone mineral density in primary adrenal insufficiency.

Authors:  Kathrin R Frey; Tina Kienitz; Julia Schulz; Manfred Ventz; Kathrin Zopf; Marcus Quinkler
Journal:  Endocr Connect       Date:  2018-05-02       Impact factor: 3.335

9.  Residual Adrenal Function in Autoimmune Addison's Disease-Effect of Dual Therapy With Rituximab and Depot Tetracosactide.

Authors:  Catherine Napier; Earn H Gan; Anna L Mitchell; Lorna C Gilligan; D Aled Rees; Carla Moran; Krishna Chatterjee; Bijay Vaidya; R Andrew James; Yaasir Mamoojee; Simon Ashwell; Wiebke Arlt; Simon H S Pearce
Journal:  J Clin Endocrinol Metab       Date:  2020-04-01       Impact factor: 5.958

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.